What is it about?
Patient specific endothelial cells, derived from diabetic macular edema patient through cell reprogramming, recapitulate clinical evaluations of anti-VEGF responsiveness and uncover a potential role for Neuronal Pentraxin 2 in patients that don't respond to anti-VEGF treatment.
Featured Image
Read the Original
This page is a summary of: Endothelial Cells Derived From Patients With Diabetic Macular Edema Recapitulate Clinical Evaluations of Anti-VEGF Responsiveness Through the Neuronal Pentraxin 2 Pathway, Diabetes, August 2020, American Diabetes Association,
DOI: 10.2337/db19-1068.
You can read the full text:
Contributors
The following have contributed to this page
